Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BellBrook expands assay portfolio
June 2020
SHARING OPTIONS:

MADISON, Wis.—BellBrook Labs recently announced the development of the Transcreener ADO CD73 Assay, a high-throughput screening assay designed to identify small-molecule modulators for the immunosuppressive extonucleotidase CD73. Adenosine (ADO) is the product of a CD73 reaction, and this assay enables users to monitor CD73 activity in a mix-and-read format with a far-red fluorescence polarization readout. A coupling enzyme is used to convert AMP to ADP, which can then be detected by the Transcreener ADP Assay. The Transcreener CD73 Assay is designed for high-throughput screening in miniaturized 384- or 1,536-well formats, and according to BellBrook, “has excellent utility for all aspects of screening and hit-to-lead, including dose-response measurements and mechanistic studies, as well as basic research on CD73 enzymology and regulation.” Research has highlighted adenosine as being an immunosuppressive agent within the tumor microenvironment, and ectonucleotidase enzymes have likewise been identified as potential targets for immuno-oncology.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.